|Status: One Wales interim decision|
Using the agreed starting and stopping criteria, abiraterone in combination with prednisolone can be made available within NHS Wales for the treatment of non-metastatic and locally advanced, high-risk, hormone-sensitive prostate cancer. High risk is defined as at least 2 of the following: tumour stage T3 or T4, a Gleason score of 8 to 10, and a PSA level of ≥ 40 ng/ml.
Abiraterone acetate should be prescribed on the basis of lowest acquisition cost.
The risks and benefits of the off-label use of abiraterone for this indication should be clearly stated and discussed with the patient to allow informed consent.
Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.
This advice will be reviewed after 12 months or earlier if new evidence becomes available.
|Medicine name||abiraterone acetate|
Treatment of non-metastatic and locally advanced, high-risk, hormone-sensitive prostate cancer
|BNF chapter||Malignant disease & immunosuppression|
|Submission type||One Wales|
|Status||One Wales interim decision|
|Date of issue||07/11/2022|